Northwest Biotherapeutics (NWBO) Debt to Equity: 2009-2025
Historic Debt to Equity for Northwest Biotherapeutics (NWBO) over the last 14 years, with Sep 2025 value amounting to -$0.16.
- Northwest Biotherapeutics' Debt to Equity rose 58.42% to -$0.16 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.16, marking a year-over-year increase of 58.42%. This contributed to the annual value of -$0.23 for FY2024, which is 48.15% up from last year.
- Per Northwest Biotherapeutics' latest filing, its Debt to Equity stood at -$0.16 for Q3 2025, which was up 14.81% from -$0.18 recorded in Q2 2025.
- Northwest Biotherapeutics' Debt to Equity's 5-year high stood at -$0.01 during Q3 2023, with a 5-year trough of -$1.06 in Q4 2021.
- Moreover, its 3-year median value for Debt to Equity was -$0.26 (2024), whereas its average is -$0.28.
- Its Debt to Equity has fluctuated over the past 5 years, first spiked by 97.98% in 2023, then slumped by 2,420.26% in 2024.
- Quarterly analysis of 5 years shows Northwest Biotherapeutics' Debt to Equity stood at -$1.06 in 2021, then surged by 36.51% to -$0.68 in 2022, then soared by 33.62% to -$0.45 in 2023, then soared by 48.15% to -$0.23 in 2024, then spiked by 58.42% to -$0.16 in 2025.
- Its last three reported values are -$0.16 in Q3 2025, -$0.18 for Q2 2025, and -$0.17 during Q1 2025.